MX2019008798A - Nueva formulacion. - Google Patents
Nueva formulacion.Info
- Publication number
- MX2019008798A MX2019008798A MX2019008798A MX2019008798A MX2019008798A MX 2019008798 A MX2019008798 A MX 2019008798A MX 2019008798 A MX2019008798 A MX 2019008798A MX 2019008798 A MX2019008798 A MX 2019008798A MX 2019008798 A MX2019008798 A MX 2019008798A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- novel formulation
- obtaining
- combination
- well
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10141—Use of virus, viral particle or viral elements as a vector
- C12N2710/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1701239.4A GB201701239D0 (en) | 2017-01-25 | 2017-01-25 | Novel formulation |
| PCT/IB2018/050453 WO2018138667A1 (en) | 2017-01-25 | 2018-01-25 | Novel formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008798A true MX2019008798A (es) | 2019-09-11 |
Family
ID=58462949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008798A MX2019008798A (es) | 2017-01-25 | 2018-01-25 | Nueva formulacion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11590243B2 (enExample) |
| EP (1) | EP3573598A1 (enExample) |
| JP (1) | JP7090089B2 (enExample) |
| CN (1) | CN110430867B (enExample) |
| BE (1) | BE1025187B1 (enExample) |
| BR (1) | BR112019015245A2 (enExample) |
| CA (1) | CA3050629A1 (enExample) |
| GB (1) | GB201701239D0 (enExample) |
| MX (1) | MX2019008798A (enExample) |
| WO (1) | WO2018138667A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| EP3587581A1 (en) * | 2018-06-26 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Formulations for simian adenoviral vectors having enhanced storage stability |
| BR112021025025A2 (pt) * | 2019-06-11 | 2022-02-22 | Glaxosmithkline Biologicals Sa | Formulações de vacinas de mucosa |
| JP2023548838A (ja) * | 2020-10-29 | 2023-11-21 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | ニワトリ貧血ウイルス（ｃａｖ）に基づくベクター |
| US20230414516A1 (en) * | 2020-11-16 | 2023-12-28 | BioNTech SE | Enhanced formulation stabilization and improved lyophilization processes |
| CN116782889A (zh) * | 2020-11-16 | 2023-09-19 | 生物技术欧洲股份公司 | 增强的制剂稳定性和改善的冻干工艺 |
| CN114903922B (zh) * | 2021-02-09 | 2024-04-26 | 武汉博沃生物科技有限公司 | 包含腺病毒的医药配制品及其保存方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| SI1409012T1 (sl) | 2001-06-22 | 2009-08-31 | Wistar Inst | Postopki za induciranje citotoksičnega imunskega odziva in za to uporabni sestavki rekombinantnih opičjih adenovirusov |
| WO2005071093A2 (en) | 2004-01-23 | 2005-08-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Chimpanzee adenovirus vaccine carriers |
| PT1954308E (pt) | 2005-09-16 | 2011-11-03 | Merial Ltd | Estabilizadores para vacinas liofilizadas |
| EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| SI2391638T1 (sl) | 2009-02-02 | 2018-10-30 | Glaxosmithkline Biologicals Sa | Nukleinskokislinske in aminokislinske sekvence opičjega adenovirusa, vektorji, ki le-te vsebujejo, in njihova uporaba |
| CN102028954B (zh) | 2009-09-29 | 2012-11-07 | 成都康弘生物科技有限公司 | 一种重组腺病毒的制剂 |
| US9526777B2 (en) | 2010-04-16 | 2016-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| BR112014008167B1 (pt) | 2011-10-05 | 2022-05-24 | Genvec Inc | Adenovírus ou vetor adenoviral e composição os compreendendo |
| CN107574154A (zh) | 2011-10-05 | 2018-01-12 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| CN103974970B (zh) | 2011-10-05 | 2018-01-02 | 金维克有限公司 | 猴腺病毒(大猩猩)或腺病毒载体及其使用方法 |
| CN102631672B (zh) | 2012-04-27 | 2014-04-02 | 天津百若克医药生物技术有限责任公司 | 一种冻干灭活乙型脑炎疫苗 |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| JP6664338B2 (ja) | 2014-06-13 | 2020-03-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組合せ物 |
-
2017
- 2017-01-25 GB GBGB1701239.4A patent/GB201701239D0/en not_active Ceased
-
2018
- 2018-01-25 BE BE2018/5040A patent/BE1025187B1/fr not_active IP Right Cessation
- 2018-01-25 JP JP2019539953A patent/JP7090089B2/ja active Active
- 2018-01-25 EP EP18703633.0A patent/EP3573598A1/en not_active Withdrawn
- 2018-01-25 MX MX2019008798A patent/MX2019008798A/es unknown
- 2018-01-25 US US16/478,232 patent/US11590243B2/en active Active
- 2018-01-25 WO PCT/IB2018/050453 patent/WO2018138667A1/en not_active Ceased
- 2018-01-25 CA CA3050629A patent/CA3050629A1/en active Pending
- 2018-01-25 CN CN201880021100.9A patent/CN110430867B/zh not_active Expired - Fee Related
- 2018-01-25 BR BR112019015245A patent/BR112019015245A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20190365930A1 (en) | 2019-12-05 |
| WO2018138667A1 (en) | 2018-08-02 |
| CA3050629A1 (en) | 2018-08-02 |
| CN110430867A (zh) | 2019-11-08 |
| EP3573598A1 (en) | 2019-12-04 |
| BR112019015245A2 (pt) | 2020-04-14 |
| JP2020506691A (ja) | 2020-03-05 |
| GB201701239D0 (en) | 2017-03-08 |
| JP7090089B2 (ja) | 2022-06-23 |
| US11590243B2 (en) | 2023-02-28 |
| CN110430867B (zh) | 2023-04-07 |
| BE1025187B1 (fr) | 2018-12-03 |
| BE1025187A1 (fr) | 2018-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008798A (es) | Nueva formulacion. | |
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| MX2016011898A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
| WO2014194034A3 (en) | Novel metalloproteases | |
| PH12017502255B1 (en) | Nrf2 regulators | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| EP3644956A4 (en) | HIGH-GLOSS, DURABLE COSMETIC COMPOSITIONS THAT ARE ALSO SUITABLE AS COSMETIC ADHESIVES | |
| EA201590887A1 (ru) | Композиция | |
| GB2600652B (en) | Novel compositions | |
| ZA202001722B (en) | Novel composition | |
| AU2014324961A8 (en) | Highly potent glucocorticoids | |
| MX345926B (es) | Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas. | |
| WO2016013030A3 (en) | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof | |
| GB201721846D0 (en) | Novel composition | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| WO2015029074A3 (en) | Compositions of eltrombopag | |
| IN2014MU00455A (enExample) | ||
| WO2016092561A3 (en) | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof | |
| MX2016014244A (es) | Metodo para secar mezclas de sabores de reaccion. | |
| PH12020550081A1 (en) | Transdermal formulations | |
| MX371443B (es) | Composiciones farmaceuticas que comprenden levocetirizina. | |
| MX2017003550A (es) | Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos. | |
| SG11202003286YA (en) | Cool-sensation imparter composition containing 2,2,6-trimethylcyclohexanecarboxylic acid derivative | |
| WO2015111004A3 (en) | Improved process for the preparation of chlorophenyl trifluoroethanone |